Complete financial analysis of Integrated BioPharma, Inc. (INBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Integrated BioPharma, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Swisscom AG (SCMWY) Income Statement Analysis – Financial Results
- Baoding Lucky Innovative Materials Co.,Ltd (300446.SZ) Income Statement Analysis – Financial Results
- Hitachi Construction Machinery Co., Ltd. (HTCMF) Income Statement Analysis – Financial Results
- Classic Filaments Limited (CFL.BO) Income Statement Analysis – Financial Results
- Shandong Head Group Co.,Ltd. (002810.SZ) Income Statement Analysis – Financial Results
Integrated BioPharma, Inc. (INBP)
About Integrated BioPharma, Inc.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.32M | 50.67M | 56.25M | 63.56M | 52.77M | 49.98M | 43.71M | 46.95M | 42.21M | 37.49M | 33.68M | 33.62M | 36.60M | 25.13M | 37.02M | 39.37M | 49.94M | 60.16M | 57.82M | 32.74M | 25.28M | 22.24M | 23.55M | 15.29M | 17.97M | 12.30M | 16.00M | 11.10M | 10.60M |
| Cost of Revenue | 46.43M | 46.61M | 49.69M | 54.08M | 46.04M | 43.76M | 38.72M | 40.29M | 36.71M | 33.10M | 28.80M | 28.12M | 29.00M | 21.36M | 29.21M | 29.59M | 41.43M | 42.74M | 35.98M | 30.74M | 19.39M | 17.11M | 18.84M | 13.82M | 16.31M | 11.30M | 12.40M | 9.20M | 8.00M |
| Gross Profit | 3.88M | 4.06M | 6.55M | 9.48M | 6.73M | 6.22M | 4.99M | 6.67M | 5.50M | 4.39M | 4.88M | 5.50M | 7.61M | 3.77M | 7.81M | 9.77M | 8.51M | 17.42M | 21.84M | 1.99M | 5.89M | 5.13M | 4.70M | 1.47M | 1.67M | 1.00M | 3.60M | 1.90M | 2.60M |
| Gross Profit Ratio | 7.72% | 8.01% | 11.65% | 14.92% | 12.75% | 12.45% | 11.41% | 14.20% | 13.04% | 11.72% | 14.50% | 16.36% | 20.78% | 15.00% | 21.11% | 24.83% | 17.05% | 28.96% | 37.77% | 6.08% | 23.30% | 23.07% | 19.98% | 9.63% | 9.27% | 8.13% | 22.50% | 17.12% | 24.53% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.28M | 0.00 | 3.26M | 0.00 | 0.00 | 4.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00K | 0.00 | 133.00K | 0.00 | 0.00 | 278.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.63M | 3.94M | 3.81M | 3.70M | 3.47M | 3.52M | 3.29M | 3.48M | 3.39M | 3.46M | 3.53M | 4.39M | 8.11M | 3.45M | 11.36M | 14.23M | 24.28M | 19.38M | 16.74M | 13.10M | 5.30M | 3.83M | 3.91M | 3.76M | 3.28M | 3.30M | 3.20M | 2.50M | 2.00M |
| Other Expenses | 0.00 | 40.00K | -93.00K | 57.00K | -274.00K | -18.00K | 101.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.20M | 0.00 | 0.00 | 0.00 | 378.64K | 400.00K | 400.00K | 300.00K | 300.00K |
| Operating Expenses | 3.63M | 3.94M | 3.81M | 3.70M | 3.47M | 3.52M | 3.29M | 3.48M | 3.39M | 3.46M | 3.53M | 4.39M | 8.11M | 3.45M | 11.36M | 14.23M | 24.28M | 19.38M | 16.74M | 13.10M | 11.50M | 3.83M | 3.91M | 3.76M | 3.66M | 3.70M | 3.60M | 2.80M | 2.30M |
| Cost & Expenses | 50.07M | 50.55M | 53.50M | 57.78M | 49.51M | 47.27M | 42.02M | 43.77M | 40.10M | 36.56M | 32.33M | 32.51M | 37.11M | 24.81M | 40.57M | 43.82M | 65.71M | 62.12M | 52.72M | 43.85M | 30.89M | 20.94M | 22.75M | 17.58M | 19.96M | 15.00M | 16.00M | 12.00M | 10.30M |
| Interest Income | 0.00 | 13.00K | 128.00K | 256.00K | 397.00K | 630.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 3.00K | 20.00K | 38.00K | 59.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 40.00K | 107.00K | 256.00K | 397.00K | 630.00K | 926.00K | 778.00K | 953.00K | 979.00K | 964.00K | 979.00K | 1.11M | 1.53M | 2.47M | 2.23M | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.22M | 1.15M | 834.00K | 826.00K | 772.00K | 774.00K | 348.00K | 393.00K | 351.00K | 405.00K | 390.00K | 425.00K | 500.00K | 361.00K | 454.00K | 517.00K | 1.62M | 1.43M | 1.17M | 1.59M | 952.53K | 455.62K | 361.33K | 353.88K | 378.64K | 400.00K | 400.00K | 300.00K | 300.00K |
| EBITDA | 1.47M | 1.27M | 3.56M | 8.33M | 4.26M | 3.45M | 2.28M | 3.58M | 2.87M | 1.34M | 1.74M | 1.51M | -1.09M | 173.00K | -3.08M | -5.60M | -14.58M | -536.00K | 6.27M | -9.53M | -4.21M | 1.75M | 1.16M | -1.93M | -1.61M | -2.30M | 400.00K | -600.00K | 600.00K |
| EBITDA Ratio | 2.93% | 2.57% | 4.98% | 10.49% | 5.98% | 6.92% | 4.90% | 7.34% | 5.84% | 3.57% | 5.17% | 4.58% | -0.01% | 2.73% | -8.31% | -9.90% | -29.19% | -1.05% | 10.73% | -37.08% | 4.61% | 6.35% | -1.48% | -14.35% | -43.45% | -17.89% | 2.50% | -6.31% | 5.66% |
| Operating Income | 251.00K | 120.00K | 1.97M | 5.78M | 2.38M | 2.70M | 1.69M | 3.19M | 2.11M | 933.00K | 1.35M | 1.12M | -506.00K | 321.00K | -3.55M | -4.45M | -15.77M | -1.96M | 5.10M | -11.11M | -5.61M | 1.30M | 798.05K | -2.29M | -1.99M | -2.70M | 0.00 | -900.00K | 300.00K |
| Operating Income Ratio | 0.50% | 0.24% | 3.50% | 9.10% | 4.52% | 5.41% | 3.88% | 6.79% | 5.01% | 2.49% | 4.01% | 3.32% | -1.38% | 1.28% | -9.59% | -11.31% | -31.57% | -3.26% | 8.83% | -33.95% | -22.19% | 5.83% | 3.39% | -14.95% | -11.07% | -21.95% | 0.00% | -8.11% | 2.83% |
| Total Other Income/Expenses | 17.00K | -20.00K | -148.00K | 1.46M | -171.00K | -662.00K | -689.00K | -1.33M | -925.00K | -64.00K | -1.13M | -1.01M | -2.20M | -1.49M | -1.94M | -3.90M | -1.47M | -639.00K | -221.62K | 2.50M | 356.89K | 363.39K | 1.49M | 189.33K | 6.05M | -100.00K | 0.00 | 0.00 | 100.00K |
| Income Before Tax | 268.00K | 100.00K | 2.60M | 7.25M | 3.09M | 2.04M | 1.01M | 1.86M | 1.19M | 869.00K | 220.00K | 110.00K | -2.70M | -1.17M | -5.50M | -8.35M | -17.23M | -2.60M | -4.88M | -8.61M | -5.25M | 1.66M | 2.28M | -2.10M | 4.06M | -2.80M | 0.00 | -900.00K | 400.00K |
| Income Before Tax Ratio | 0.53% | 0.20% | 4.62% | 11.40% | 5.85% | 4.09% | 2.30% | 3.95% | 2.82% | 2.32% | 0.65% | 0.33% | -7.38% | -4.64% | -14.84% | -21.21% | -34.51% | -4.32% | -8.44% | -26.29% | -20.77% | 7.46% | 9.70% | -13.71% | 22.57% | -22.76% | 0.00% | -8.11% | 3.77% |
| Income Tax Expense | 156.00K | 134.00K | -1.24M | -766.00K | -1.02M | 354.00K | 326.00K | -490.00K | 231.00K | 134.00K | 89.00K | 17.00K | 11.00K | 25.00K | 40.00K | 4.78M | 934.00K | -518.00K | -3.36M | -27.33K | 87.69K | 765.57K | 891.43K | -647.47K | 914.06K | -200.00K | 100.00K | -200.00K | 100.00K |
| Net Income | 112.00K | -34.00K | 3.84M | 8.01M | 4.11M | 1.69M | 679.00K | 2.35M | 958.00K | 735.00K | 131.00K | 93.00K | -2.71M | -2.28M | -5.54M | -18.18M | -18.17M | -2.04M | 8.43M | -8.58M | -5.34M | 894.12K | 1.39M | -1.45M | 3.14M | -2.60M | -100.00K | -700.00K | 300.00K |
| Net Income Ratio | 0.22% | -0.07% | 6.82% | 12.61% | 7.78% | 3.38% | 1.55% | 5.00% | 2.27% | 1.96% | 0.39% | 0.28% | -7.41% | -9.08% | -14.95% | -46.17% | -36.38% | -3.40% | 14.58% | -26.21% | -21.12% | 4.02% | 5.92% | -9.48% | 17.49% | -21.14% | -0.63% | -6.31% | 2.83% |
| EPS | 0.00 | 0.00 | 0.13 | 0.27 | 0.14 | 0.06 | 0.02 | 0.11 | 0.05 | 0.03 | 0.01 | 0.00 | -0.13 | -0.11 | -0.27 | -0.93 | -1.26 | -0.15 | 0.43 | -0.68 | -0.48 | 0.12 | 0.22 | -0.24 | 0.61 | -0.50 | -0.02 | -0.17 | 0.07 |
| EPS Diluted | 0.00 | 0.00 | 0.12 | 0.25 | 0.13 | 0.06 | 0.02 | 0.10 | 0.05 | 0.02 | 0.01 | 0.00 | -0.13 | -0.11 | -0.27 | -0.93 | -1.26 | -0.15 | 0.34 | -0.68 | -0.48 | 0.09 | 0.20 | -0.24 | 0.60 | -0.19 | -0.02 | -0.17 | 0.07 |
| Weighted Avg Shares Out | 30.07M | 29.95M | 29.84M | 29.70M | 29.57M | 28.93M | 30.32M | 21.12M | 21.11M | 21.11M | 21.08M | 21.08M | 21.01M | 20.78M | 20.47M | 19.61M | 14.38M | 13.59M | 12.83M | 12.61M | 11.11M | 7.77M | 6.23M | 5.96M | 5.17M | 5.18M | 4.73M | 4.01M | 4.01M |
| Weighted Avg Shares Out (Dil) | 30.87M | 29.95M | 32.32M | 32.11M | 31.16M | 29.59M | 30.32M | 30.17M | 21.19M | 29.39M | 21.19M | 21.24M | 21.01M | 20.78M | 20.47M | 19.61M | 14.38M | 13.59M | 16.23M | 12.61M | 11.11M | 10.42M | 7.11M | 5.96M | 5.26M | 13.58M | 4.73M | 4.01M | 4.01M |
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024
HILLSIDE, NJ / ACCESSWIRE / November 13, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2024. Revenue for the quarter ended September 30, 2024 was $13.6 million compared...
Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024
HILLSIDE, NJ / ACCESSWIRE / September 20, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2024. Revenue for the quarter ended June 30, 2024 was...
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024
HILLSIDE, NJ / ACCESSWIRE / May 10, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023...
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023
HILLSIDE, NJ / ACCESSWIRE / February 12, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared...
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023
HILLSIDE, NJ / ACCESSWIRE / November 9, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2023. Revenue for the quarter ended September 30, 2023 was $12.9 million compared...
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023
HILLSIDE, NJ / ACCESSWIRE / September 15, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2023. Revenue for the quarter ended June 30, 2023 was...
OTC Markets Group Welcomes Integrated BioPharma, Inc. to OTCQX
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Integrated BioPharma, Inc. (OTCQX: INBP), a vitamins, nutritional supplements and herbal products company, has qualified...
Integrated BioPharma: Strong Growth For Less Than A 5 P/E
The company's quarterly results saw revenue increase 33% and earnings increase 233% to $0.04 per share. With a current share price of about $0.60, the stock is trading for under 4x trailing earnings.
Source: https://incomestatements.info
Category: Stock Reports